Clinical study results presented at

United European Gastroenterology (UEG) Week 2016

 

A new blood test to assess the risk of Colorectal Cancer (CRC)
Measurement of Natural Killer Cell Activity (NKA) in patients undergoing colonoscopy.

 

CLINICAL STUDY DETAILS

This study was conducted at Maisonneuve-Rosemont Hospital in Montreal, Quebec, Canada by Dr. Gilles Jobin and colleagues. 1047 successive subjects >40 years of age, who underwent colonoscopy, were recruited between October 2014 and January 2016. NK VueTM a novel in vitro diagnostic device (IVDD), was used to measure NKA in these subjects. NKA was compared in subjects with cancer-negative colonoscopies to those with pathologically confirmed CRC.

Preliminary study resultsare presented today at United European Gastroenterology (UEG) Week 2016 by Dr. Gilles Jobin, chief of gastroenterology, Maisonneuve-Rosemont Hospital, Montreal, for the 869 subjects where complete subject files were available at the time of statistical analysis.

 

CLINICAL STUDY RESULTS

Briefly, in the 762 evaluable subjects, statistically significant differences were found between the NKA of patients positive for CRC (n=21), confirmed by colonoscopy and pathological verification, and that of patients negative for CRC (n=741) (CRC mean 344.2 pg/mL, CRC-negative mean 731.5 pg/mL, p=0.001; CRC median 87.0 pg/mL, CRC-negative median 294.8 pg/mL, p<0.001). At a cut-off of 200 pg/mL, sensitivity of the IVDD for the detection of CRC was 85.7%, with a specificity of 59.6%, with positive and negative predictive values of 5.7% and 99.3%, respectively. The present study using a new simple blood test confirms that the measurement of NKA may be a useful tool in clinical practice to assess the risk of CRC.

 

ABOUT NK VUE

NK Vue is the first commercially available IVDD that measures NKA in a small volume of stimulated whole blood. This IVDD was approved by Health Canada in December 2014 for the monitoring of the immune status of individuals. For additional information on NKA, the NK Vue test or ATGen Canada Inc., please visit www.atgencanada.com.

 

This press release may contain forward-looking statements and predictions.
These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.
Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release.

 

For Media inquiries please contact Gaétan Huneault, President at 1-855-561-4681, extension 201.